© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Efinaconazole didn’t pop up overnight. Decades of stubborn foot fungus complaints nudged researchers to look for new weapons against the tough dermatophytes under our nails. As a kid who played soccer, toenail fungus brought plenty of embarrassment, yet older topical drugs frustrated so many. After older azole antifungals struggled to penetrate the nail plate, scientists at Kaken Pharmaceutical in Japan tracked new molecular tweaks—eventually patenting efinaconazole. Regulatory nods took patience, with the FDA finally approving a 10% topical solution known as Jublia in 2014. This wasn’t just luck; clinical trials stretching over years had to prove it could outperform rivals like ciclopirox and amorolfine. Japan and North America led the first launches while evidence kept mounting that this solution could finally slip through nail keratin’s tough barriers.
Efinaconazole stands out as a triazole antifungal agent targeting common causes of onychomycosis, or nail fungus. Unlike older formulations that clung to nails but struggled to reach fungal roots, it seeps directly through the nail’s microstructure. Jublia and related brands appear as clear, colorless-to-yellowish solutions, packaged with brush-on applicators that let users coat the nail and cuticle in just seconds. Doses are safe for adults and teens; treatments last for nearly a year on average. Companies such as Valeant, Upsher-Smith, and generics offer the drug worldwide, each aiming to beat stubborn fungal infections that ignore basic hygiene or drugstore remedies.
Under the microscope, efinaconazole presents as a white to light yellow crystalline powder, with a melting point straddling 84 to 89 °C. It dissolves freely in alcohol, ethanol, and DMSO yet barely budges in water. The molecule features a triazole ring—a backbone for binding fungal cytochrome P450 enzymes—plus halogen substitution (chlorine and fluorine) that helps the drug resist breakdown. Its chemical formula: C18H22Cl2FN3O, and a molecular mass of 401.3 g/mol, spell out a small, lipophilic drug custom-built for deep nail penetration.
Manufacturers stamp labels with purity requirements hovering above 98%, as impurities could cut into both shelf stability and patient safety. Liquid solutions remain stable in light-protected, airtight containers at standard room temperature. Export documents carry hazard codes and storage rules that protect both shipping handlers and pharmacists. Since 10% solution is the customary strength, health agencies focus on that benchmark. Labels demand batch numbers, expiry dates, and the United States Pharmacopeia (USP) or Japanese Pharmacopeia (JP) standards. Every bottle reveals clear instructions—single daily application, avoid contact with eyes, and the need for persistence over months. Most clinicians warn patients that visible results lag behind the behind-the-scenes cleanup happening under the nail plate.
Synthesizing efinaconazole involves linking a substituted phenyltriazolyl alcohol with halogenated side chains. Kaken and collaborators disclosed multi-step processes: early steps introduce the triazole ring, with Friedel-Crafts alkylation or halogenation to add the right aromatics. Grignard reactions and catalytic hydrogenation produce intermediates, which then undergo alkylation to yield the active compound. Careful control of pH, temperature, and reagent purity determines the yield and cuts down on unwanted byproducts. The final step crystallizes and purifies the substance, washing away reactive solvents and any catalyst residue.
Researchers keep hunting for analogs or tweaks to efinaconazole that might cut down on side effects, cost, or resistance. Swapping halogen placement, altering triazole ring substituents, or adjusting alkyl side chains keeps the core pharmacophore but bumps up solubility or selectivity. The molecule’s triazole group intercepts ergosterol synthesis enzymes in fungi, hopping into the iron atom of cytochrome P450 14α-demethylase to plug its activity. Chemical tweaking of this “warhead” sometimes yields versions with even greater fungal selectivity or less human enzyme inhibition. Modifications also play with different salt forms, such as efinaconazole hydrochloride, improving topical absorption or stability.
Official databases recognize efinaconazole by its IUPAC name: (2R,3R)-2-(2,4-difluorophenyl)-1,3-dihydroxypropyl-1H-1,2,4-triazole. Drug indexes note a list of synonyms—EHC 7706, KP-103, Jublia, and trade names unique to different territories. China, India, and Europe list their own generic filings, usually labeled under simple “Efinaconazole Topical Solution 10%.” Pharmacies stock it as Jublia or homegrown labels, while researchers order powder grades for in vitro and in vivo studies. All labels echo the CAS number 861068-74-4 for cross-checking purity lots.
Safety rests on years of skin irritation, allergy, and toxicity screening. Standard application rarely triggers burning or stinging, besides occasional localized redness or itch. Its low systemic absorption means you don’t see the liver or endocrine side effects of oral azoles, which brings relief to anyone with chronic health issues—or daily drug regimens. Handling the raw material or large amounts does bring hazards: lab staff wear gloves, dust masks, and eye protection, as the powder irritates both mucous membranes and eyes. Shipping falls under UN3077 (environmentally hazardous) rules for bulk lots but not for finished, consumer-ready solutions. Pharmacists and researchers follow Material Safety Data Sheets (MSDS) balancing ease of use with caution, always disposing of expired bottles by burning or chemical neutralization.
Few human health problems annoy like stubborn toenail fungus. Efinaconazole delivers real-world results in onychomycosis, including tough cases caused by Trichophyton rubrum and Trichophyton mentagrophytes. Diabetic and elderly patients especially benefit, dodging the hepatic monitoring of oral terbinafine. Podiatrists, dermatologists, and even general practitioners recommend the drug to soccer moms, elderly patients, and anyone embarrassed by thick, yellow, crumbling nails. Athlete’s foot, ringworm, and other superficial dermatomycoses show some sensitivity, though the official label only certifies its use for infected nails. Veterinarians and academic mycology labs sometimes request the pure powder for experiments on pet fungal species, always looking for the next clinical breakthrough.
Across academic labs, efinaconazole earns attention for its stubborn resistance to metabolic breakdown, as well as the rare emergence of clinically significant fungus resistance. Clinical researchers compare treatment durations, cure rates, relapse after therapy, and combined therapies (e.g., with laser or debridement). Early publications from the 2000s focused heavily on nail penetration studies, revealing the molecule’s low surface tension compared to rivals. Modern R&D branches into new delivery methods: foam, spray, hydrogels, and even microneedle patches. Genomic studies mash up fungus DNA with repeated efinaconazole exposure, searching for mutations that might warn of incoming resistance. Even as generics squeeze the price, patent owners keep tweaking analogs and delivery platforms, seeking faster or easier outcomes for patients.
Chronic safety matters deeply, especially for drugs that linger on the body for months. Systemic toxicity studies in rats, rabbits, and dogs show little absorption into the bloodstream—most of the drug stays put at the application site. Doses up to 150-fold the human equivalent never triggered organ damage in those animals; indeed, human trial subjects almost never recorded measurable blood levels on routine labwork. Mutagenicity and carcinogenicity trials ran for two years or longer without worrisome findings. In new rat embryo models and adult sheep, reproductive toxicity didn't appear, either. There’s always a subset at risk for contact dermatitis or rare cross-hypersensitivity among azoles, so the warning box covers anyone with a history of skin drug reactions. Environmental toxicity earns less attention; the key concern focuses on pharmaceutical waste building up in water systems from discarded doses or expired stock.
Toe fungus remains one of those unsolved public health hassles, with personal embarrassment often overshadowed by risk of secondary bacterial infections or even hospitalization for diabetics. Efinaconazole, with its stability, deep reach, and patient-friendly safety, promises a steady future on pharmacy shelves. Researchers want shorter courses, faster action, and broader fungus coverage. Combinations with drugs or topical steroids could tackle mixed infections or ease application-site itch. Smart packaging—think single-use vials for nursing homes or mobile clinics—might cut long-term reinfection rates. Academic teams keep pressing for greener production, minimizing hazardous solvents, and improving yield efficiency—an effort to keep the drug accessible as populations age. Big data from electronic health records could pinpoint regional resistance pockets, prompting local tweaks in nail infection guidelines. Nail health carries quiet stigma, yet innovation in this field holds the promise of improving both the confidence and quality of life for millions worldwide.
Living with toenail fungus can feel embarrassing and frustrating. The condition means thickened nails, yellow stains, and a reluctance to show bare feet. The search for real relief brings many to efinaconazole. This prescription medicine comes as a topical solution, most often known by the brand name Jublia. It’s designed specifically to treat fungal nail infections—what your doctor calls onychomycosis.
Years ago, treatment choices for nail fungus boiled down to either over-the-counter creams that failed to penetrate the thick nail, or harsh oral pills that some found tough on the liver. Efinaconazole changed that landscape. It acts as an antifungal by punching holes in the cell membranes of the fungus. The medicine gets through the nail plate right to the spot where the fungus hides. Clinical studies showed that after almost a year of using efinaconazole daily, more people ended up with clear nails compared to those using plain solutions without the key ingredient.
Those who have dealt with nail fungus often share the same story: embarrassment at the pool, hiding their feet in sandals, and disappointment at how slow improvement comes. I’ve seen close friends frustrated with home remedies, vinegar soaks, and treatments marketed with empty promises. Efinaconazole doesn’t work overnight either. The process takes patience—many don’t see major change until after ten months of steady application. Still, knowing that research backs up your effort seems to help folks stick with the plan, even when progress runs slow.
Side effects tend to stay mild—some notice redness or irritation around the nail. That's usually where things stop. For those who struggle with liver problems and want to avoid oral pills, sticking with a topical like efinaconazole may feel safer. The Food and Drug Administration signed off on its use after sifting through large studies. Still, not everyone finds full success. Nail fungus stays hard to treat because much of the fungus hides deep under the nail. Sometimes, not even the best topical medicines reach every last bit of infection.
Cost stands out as a nagging problem with prescribed treatments like efinaconazole. Without insurance, the monthly bill strains most budgets. Even with coverage, patients hit roadblocks from strict prior authorization rules. People might do better if they spot fungus early—most wait too long, allowing the infection to spread. Community pharmacy teams could start the conversation, getting more people pointed toward a solution before the issue gets out of hand.
Sometimes, the answer lies in setting clear expectations. No medicine creates miracle overnight improvement—the journey from discolored, thickened nail to clearer growth takes time. Picking an antifungal backed by strong clinical evidence, sticking with daily use, and talking with your healthcare provider at the first sign of trouble seems to bring the best odds for healthy nails.
1. Gupta, A. K., et al. "Efinaconazole topical solution for treatment of toenail onychomycosis." Journal of Drugs in Dermatology, 2014.2. U.S. Food & Drug Administration. "FDA approves Jublia for treatment of toenail fungus." Published 2014.3. Elewski, B. E., et al. "Efinaconazole topical solution, 10% in the treatment of toenail onychomycosis: a pooled analysis of two Phase III studies." Journal of the American Academy of Dermatology, 2013.
Efinaconazole entered the scene as a real game changer for people fighting stubborn nail fungus. It’s tough to feel comfortable in sandals or barefoot at the gym when one or more toenails are thick, discolored, or crumbly. I’ve seen a family member struggle for years with drugstore creams and home remedies before finally meeting this prescription solution. Efinaconazole, known as Jublia, works as a topical triazole antifungal—applied right to the nail so it targets the infection at its home base.
Using efinaconazole isn’t just about squeezing liquid onto the nail. From experience, I know that overlooked steps waste months of nightly effort. The trick lies in giving the medication a real chance to reach the fungus buried under nail layers. Clean feet matter as much as timing—soaping the toes and drying them off well sets the stage for treatment. Fungal infections thrive in damp darkness, so don’t skip this part.
After an evening shower, my relative sat with her feet up and clear instructions in hand. We used the brush that comes with the bottle, painting a thin coat over the entire nail. The doctor drilled the point home: get under the tip and around the sides, not just the top. Fungi hide where the nail lifts off the skin, so these corners become essential battlegrounds. Rushing this step sacrifices results.
We found that patience carried the most weight. Each night required the same slow, thoughtful application—no skipping days. She waited at least ten minutes before putting on socks or climbing into bed, so the solution didn’t rub off. Manufacturers say the formula absorbs quickly, but immediate contact with bedding or shoes could undo the work. We placed a small fan by her chair, helping things dry faster and keeping the habit from feeling like a chore.
Clinical studies referenced in The Journal of the American Academy of Dermatology show efinaconazole outperforms many older antifungals in reaching the infection site. My relative’s podiatrist emphasized that daily consistency, good hygiene, and regular trimming of affected nails offer the best shot at clear results. Some patients lose hope after a month, but research shows visible improvement often appears after 24 weeks or more of steady treatment. We marked the calendar to track progress, so the slow change would not be so discouraging.
One problem I noticed—folks don’t think to thin the nail. Filing thickened nails a couple of times each week let the medication really soak in. Skipping this step leads to wasted product and barely any improvement. Sticking to simple, unscented soaps also makes a difference; harsh soaps won’t help clear the infection faster and could dry surrounding skin out, making matters worse. Dry shoes and clean socks cut down on reinfection risks. Wearing old, damp shoes only undermines the hard work done each evening.
Staying motivated proves hard with slow treatments like this. Setting reminders on your phone or partnering with a supportive family member breaks up monotony. Doctors tell me oral antifungal pills sometimes finish the job when topical solutions plateau, but efinaconazole gives many a fighting chance without the risks to liver health that come with pills. Taking photos each month and tossing out moldy old socks tells the infection it’s not welcome. If you want results, small habits matter more than miracle cures or shortcuts.
Efinaconazole often surfaces in doctors’ offices and medicine cabinets as a go-to solution for nail fungus. Many see results and get back to normal life. This topical antifungal, sold as Jublia, wins points for convenience and ease of use. Its liquid formulation skips the pill’s demands on your liver and offers direct action where fungus thrives. Despite its upsides, users report some bumps along the road. Side effects deserve attention, especially since no medicine acts in a vacuum.
Most folks apply Efinaconazole without much drama. For some, though, skin near the treated nail reacts. Redness shows up as an early sign. Mild pain or irritation at the application site can follow. Others report itching, burning, and swelling around their nails. These reactions seem to pass without major problems in most cases.
FDA approval documents and real-world experience say serious side effects remain rare. An allergic reaction stands out as an outlier but demands immediate care—think swelling of lips or face, or trouble breathing. These don’t pop up in most cases, but no one wants to gamble with their health.
Some users talk about blisters, ingrown toenails, or the surrounding skin getting thicker or peeling. These issues won’t knock everybody out of their routine, but they do raise eyebrows—especially in people with sensitive skin or conditions like eczema.
The nail can get damaged further by repeated application. White or yellow streaks might appear as nails grow out, making it hard to tell if the medication helps or if fungus keeps spreading. Sometimes, this leads to frustration and even quitting the treatment.
Clinical trials give Efinaconazole a solid safety record. In one phase of trials, less than 5 percent of users reported local skin irritation. Very few saw enough discomfort to stop using it. No evidence so far shows the medication triggering internal organ problems, thanks to low absorption into the bloodstream.
Studies, including guidance from major dermatology groups, still stress the need to watch for worsening or spreading reactions. Those with weakened immune systems or diabetes see more complications, so extra caution and doctor follow-ups count.
Doctors suggest staying consistent with cleaning and drying nails before each dose. Skipping polish or fake nails lets medication sink in without barriers. Using a thin coat limits the risk of overexposure. If symptoms flare up, swapping to another treatment or pausing Efinaconazole sometimes solves the problem.
Pharmacists stand ready to talk through drug interactions, though topical Efinaconazole rarely mixes with other prescriptions in ways that spark trouble. Anyone seeing unexpected blisters, rashes, or pain that grows worse should check in with a healthcare provider, not just power through.
Fact-based care, honest reports from users, and awareness from both prescriber and patient build a safer path. As always, the best option means balancing good outcomes against any unwanted side effects, with a human touch behind every decision.
Toenail fungus has a stubborn streak. Anyone who’s dealt with brittle, discolored nails knows it’s a slow battle. Efinaconazole, sold as Jublia, offers hope for people frustrated by the lack of progress from older creams or home remedies. In the clinic, folks expect quick fixes—days or weeks. The truth is, treating fungal nails demands a different mindset. Efinaconazole works directly where the fungus lives: the nail and surrounding skin. The visible improvements lag behind the underlying healing, so the time frame catches many off guard.
Doctors usually recommend applying Efinaconazole once a day. Most studies say the minimum recommended course lasts 48 weeks. That’s just about a year. For perspective, my cousin struggled with big toenail fungus after years of ignoring slow changes. Once she started Efinaconazole, weekly photos became her way of tracking progress. At month three, things looked the same—maybe even a little worse as the old nail grew out. Month six brought the faintest bit of clear nail at the base. By the end of a year, the healthy nail replaced more than half the old, crumbly one. Not every nail looked perfect, but walking barefoot felt much less embarrassing.
Fungal spores dig deep. Nails grow about 1-2 mm per month on toes, so any medicine must stay in place and work slowly as fresh nail pushes forward. Efinaconazole attacks the fungus cell membrane, starving it of the stuff it needs to survive. Over months, healthy nail growth crowds out the infection. Results depend on sticking to the daily routine. Missing applications, or abandoning the treatment too soon, lets the fungus bounce right back.
Randomized trials show only about 15-18% of people get a completely clear nail after using Efinaconazole for a year. That doesn't sound impressive at first. But partial improvement—less crumbling, a thicker nail, fewer color changes—happens in many more. Modern studies out of Japan and the US both highlight this slow but real progress. The best responses show up in early, mild infections. Older folks, people with diabetes, or anyone with longstanding thick nails might take longer or see less dramatic clearing. That's not a failure of the medicine, just a reminder of how tough nail fungus really is.
Nail fungus saps confidence and gets under the skin, sometimes literally. I remind people that patience plays the biggest role in success. Stopping early, skipping days, or expecting overnight miracles leads to disappointment. Some people add regular toenail trimming and gentle filing to speed up the visual progress. Others work with a podiatrist to thin very thick nails, so the medicine gets in deeper.
A clean, dry foot matters. Socks that wick moisture, shoes with enough airflow, and throwing out old, infected pairs help tamp down re-infection. People dealing with immune compromise or diabetes should get a podiatrist involved early. If the topical route doesn’t budge things after many months, oral antifungal pills remain an option, though they bring their own set of side effects and monitoring needs.
Efinaconazole sets expectations straight: Nail fungus doesn’t clear in a few weeks. It’s a long haul, but visible change rewards those who commit. I’ve seen how even a halfway healthy nail makes sandals or pool trips something to look forward to rather than dread. Patience and daily care make the real difference in the journey.
I remember the first time a friend of mine showed me the yellow, thickened nail on his big toe. He looked embarrassed but mostly frustrated. Over-the-counter creams didn’t help. The mail-order mixtures smelled horrible. After months, he visited his doctor, who scribbled out a prescription for efinaconazole. It made me wonder: why does someone need a prescription for a toenail fungus solution? In an age where you can order most things online, why not this?
Efinaconazole is a potent antifungal for those tough nail infections that rarely clear up on their own. The stuff you find at a drugstore might work for light skin fungus, but nails trap infection deep inside. Efinaconazole breaks into the nail structure and stops the fungus at its roots. The issue: it is strong medicine, with a risk of irritation or, rarely, allergy. Many people have other health problems that make certain antifungals risky. The FDA keeps it behind the counter for that reason.
Doctors know how to spot other problems that look like fungus—psoriasis, trauma, even bacterial infection. Sometimes folks try to treat a crooked nail or dark streak with anything that claims “antifungal” on the label, wasting money and time. With a prescription, you get a real diagnosis and proper guidance. This protects patients and stops misuse.
It’s tempting to wish for cheaper, easier solutions. At one point in my life, I ordered supplements and herbal extracts online, hoping to treat a stubborn rash. It didn’t work, and I ended up at a clinic anyway. A recent American Academy of Dermatology survey shows that nearly half of people with nail fungus never seek treatment from a provider—they try home remedies first. Without the right therapy, nail fungus spreads, pain increases, and in people with diabetes, even minor infections can turn serious.
With efinaconazole, cost gets high. Patients often see sticker shock at pharmacies. Not every plan covers the drug, and cash prices run several hundred dollars a bottle. This keeps some Americans looking for online pharmacies or foreign versions—many times landing on shady sites with unverified ingredients.
Short-term, patients benefit from open conversations with healthcare providers. Many don’t realize that samples or generics can be available, or that certain discount cards help bring costs down. Some pharmacy chains also compile manufacturer coupon resources, which the pharmacist can walk you through.
Doctors and pharmacists both stress nail care basics—keeping nails dry, avoiding shared nail tools, and quick checkups for new changes in nail color or shape. Early diagnosis curbs the severity of infection and reduces health complications.
On a bigger scale, better insurance coverage and patient education make a real impact. Advocacy from groups like the National Psoriasis Foundation and the American Podiatric Medical Association nudges insurance companies to consider wider coverage options for proven fungal drugs. Telemedicine also paves way for faster prescriber access.
Efinaconazole sits in the prescription category for clear reasons: its power, its risks, and the knowledge doctors bring to safe use. People battling nail fungus deserve workable, trustworthy options—along with practical tools and guidance to make recovery less of an uphill fight.
| Names | |
| Preferred IUPAC name | (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol |
| Other names |
Jublia KP-103 |
| Pronunciation | /ˌɛfɪnəˈkəʊnəˌzoʊl/ |
| Identifiers | |
| CAS Number | [882257-11-6] |
| 3D model (JSmol) | `3D model (JSmol)` string for **Efinaconazole**: ``` CC1=CN(C2=CC=CC=C2C1=O)C3=CC(=C(C=C3)F)OCCOCCN4CCC(CC4)C5=CC=CC(=C5)F ``` |
| Beilstein Reference | 1363008 |
| ChEBI | CHEBI:77914 |
| ChEMBL | CHEMBL2105756 |
| ChemSpider | 10482023 |
| DrugBank | DB09039 |
| ECHA InfoCard | 100004116649 |
| EC Number | 64302-81-0 |
| Gmelin Reference | 784271 |
| KEGG | D09730 |
| MeSH | D000077342 |
| PubChem CID | 24812759 |
| RTECS number | VI995A993A |
| UNII | Y7DT0PI15A |
| UN number | UN3272 |
| Properties | |
| Chemical formula | C18H22F2N4O |
| Molar mass | 348.326 g/mol |
| Appearance | Colorless to pale yellow clear liquid |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 2.7 |
| Vapor pressure | 4.2 × 10⁻⁹ mmHg at 25°C |
| Acidity (pKa) | 14.13 |
| Basicity (pKb) | 12.1 |
| Magnetic susceptibility (χ) | -63.5e-6 cm^3/mol |
| Refractive index (nD) | 1.540 |
| Viscosity | 41.8 mPa·s |
| Dipole moment | 4.12 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -5896.6 kJ/mol |
| Pharmacology | |
| ATC code | D01AE54 |
| Hazards | |
| Main hazards | May cause eye irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | H317, H361, H410 |
| Signal word | Warning |
| Hazard statements | H317: May cause an allergic skin reaction. |
| Precautionary statements | Keep out of reach of children. For external use only. Avoid contact with eyes, mouth, and mucous membranes. If irritation occurs, discontinue use and consult a healthcare provider. Use only as directed by your physician or healthcare provider. |
| Flash point | > Efinaconazole has a flash point of **252.3 °C** |
| Autoignition temperature | autoignition temperature: 400°C |
| Lethal dose or concentration | LD50 oral rat > 1000 mg/kg |
| LD50 (median dose) | > 1,500 mg/kg (rat, oral) |
| NIOSH | WH6600000 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | Topical antifungals |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Itraconazole Fluconazole Voriconazole Posaconazole |
